NCT07691502 Coronary Computed Tomography Angiography (CCTA) for the Pre-procedural Planning of Percutaneous Coronary Intervention
| NCT ID | NCT07691502 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Minneapolis Heart Institute Foundation |
| Condition | Coronary Artery Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-08-31 |
| Primary Completion | 2028-07-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2026-08-31 with a primary completion date of 2028-07-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The CT-PLAN PCI trial will evaluate whether CCTA-guided PCI improves procedural efficiency compared with routine PCI (without pre-procedural CCTA-guidance for PCI planning) using procedural time as the primary endpoint. Key secondary outcomes will include contrast volume, radiation dose, fluoroscopy time, resource utilization, and periprocedural outcomes including post-PCI physiology, and peri-procedural myocardial injury measured by high-sensitivity cardiac troponin assays.
Eligibility Criteria
Inclusion Criteria: * At least one moderate-severe coronary stenosis on CCTA with an FFRCT ≤0.80 involving no more than two vessels (i.e. target lesion(s) must be FFRCT eligible) * Referral for non-emergent PCI of at least one de novo stenosis in a native coronary artery with a reference diameter ≥2 mm on CCTA. Exclusion Criteria: * Multivessel CAD involving ≥3 vessels. * Severe left main disease \>50% * Prior CABG * Prior PCI in target vessel * Planned CABG * Chronic coronary total occlusion in the target vessel * ST-elevation myocardial infarction * Emergent PCI * Cardiac arrest * Cardiogenic shock * Scenarios where FFRCT is not possible: inadequate CCTA quality for FFRCT, small vessels \<2 mm, with stents at the target vessel. * Unstable high-risk NSTE-ACS (hemodynamic instability, refractory angina, unstable arrhythmias, persistent ischemia). * Patients who are pregnant or nursing or plan to be pregnant in the period up to 2 years following the index procedure will not be approached due to exposure to fluoroscopy.
Frequently Asked Questions
Who can join the NCT07691502 clinical trial?
This trial is open to participants of all sexes, aged 22 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07691502 currently recruiting?
Yes, NCT07691502 is actively recruiting participants. Visit ClinicalTrials.gov or contact Minneapolis Heart Institute Foundation to inquire about joining.
Where is the NCT07691502 trial being conducted?
This trial is being conducted at Minneapolis, United States.
Who is sponsoring the NCT07691502 clinical trial?
NCT07691502 is sponsored by Minneapolis Heart Institute Foundation. The trial plans to enroll 200 participants.